Case Report
Copyright ©The Author(s) 2023.
World J Clin Cases. Jun 26, 2023; 11(18): 4295-4305
Published online Jun 26, 2023. doi: 10.12998/wjcc.v11.i18.4295
Table 1 Immunophenotype of bone marrow and chest wall tumor
Expression
Molecular marker
The immunophenotype of BMMNCs by flow cytometry
Group A49.64%
ExpressionCD34, CD13, CD117
Partial expressionCD33, HLA-DR
No expressionCD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD14, CD15, CD19, CD20, CD36, CD56, CD64, CD23
Group B22.21%
ExpressionCD19, CD20, Kappa
Partial expression
No expressionCD103, CD25, CD11c, CD34, CD117, CD5, CD10, CD23, lambda
The immunohistochemical analysis of bone marrow biopsy
ExpressionCD10, CD20, CD34, CD43, CD117, PAX-5, MPO, silver dyeing
Partial expression
No expressionBCL-6, CD3, CD5, MPO
The immunohistochemical analysis of chest wall tumor
ExpressionKi-67 (70%), CD20, PAX-5, CD10, MUM-1, BCL-6, c-MYC (< 40%), BCL-2 (< 50%)
Partial expression
No expressionCD3, CK-pan, TTF, NapsinA, CK7, P40, CK5/6, Syn, CgA, CD56, EBER